In This Article:
- By GF Value
The stock of Novo Nordisk A/S (NYSE:NVO, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $67.78 per share and the market cap of $156.4 billion, Novo Nordisk A/S stock is believed to be fairly valued. GF Value for Novo Nordisk A/S is shown in the chart below.
Because Novo Nordisk A/S is fairly valued, the long-term return of its stock is likely to be close to the rate of its business growth, which averaged 6.4% over the past three years and is estimated to grow 6.31% annually over the next three to five years.
Link: These companies may deliever higher future returns at reduced risk.
Investing in companies with poor financial strength has a higher risk of permanent loss of capital. Thus, it is important to carefully review the financial strength of a company before deciding whether to buy its stock. Looking at the cash-to-debt ratio and interest coverage is a great starting point for understanding the financial strength of a company. Novo Nordisk A/S has a cash-to-debt ratio of 1.23, which is worse than 80% of the companies in Biotechnology industry. GuruFocus ranks the overall financial strength of Novo Nordisk A/S at 7 out of 10, which indicates that the financial strength of Novo Nordisk A/S is fair. This is the debt and cash of Novo Nordisk A/S over the past years:
Investing in profitable companies carries less risk, especially in companies that have demonstrated consistent profitability over the long term. Typically, a company with high profit margins offers better performance potential than a company with low profit margins. Novo Nordisk A/S has been profitable 10 years over the past 10 years. During the past 12 months, the company had revenues of $19.7 billion and earnings of $2.786 a share. Its operating margin of 42.64% better than 96% of the companies in Biotechnology industry. Overall, GuruFocus ranks Novo Nordisk A/S's profitability as strong. This is the revenue and net income of Novo Nordisk A/S over the past years: